BioSpace News Archive

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous (IV) formulation of TPOXX for the treatment of smallpox.

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced topline results from the Phase 1 placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics and neurocognitive effects of MM-110 in 108 healthy volunteers.

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as a potential treatment for Friedreich’s ataxia will be featured in two upcoming poster presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress.

ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, announced that its 2022 Annual Meeting of Stockholders will be conducted virtually.

AIM ImmunoTech Inc. announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

Amedisys, Inc., a leading provider of home health, hospice, personal care and high-acuity care, has been selected by Modern Healthcare as one of the 2022 Best Places to Work in Healthcare for the second consecutive year.

Enlivex Therapeutics Ltd. announced that company management will present a corporate overview and participate in virtual one-on-one investor meetings during the H.C. Wainwright Global Investment Conference, which is taking place from May 23 – 26, 2022.

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2022 and provided a business update.

4C Medical Technologies, Inc. presented its global clinical experience from its initial AltaValve Early Feasibility Study cases at the American Association for Thoracic Surgery 2022 Mitral Conclave Workshop on May 13, 2022 in Boston, MA.

Myeloid Therapeutics, Inc. (“Myeloid” or the “Company”), today announced that it has entered into an agreement with Acuitas Therapeutics (“Acuitas”), a global leader in developing LNP delivery systems that enable mRNA-based therapeutics.